177 related articles for article (PubMed ID: 36984678)
1. On the Mechanism of Membrane Permeabilization by Tamoxifen and 4-Hydroxytamoxifen.
Ortiz J; Teruel JA; Aranda FJ; Ortiz A
Membranes (Basel); 2023 Feb; 13(3):. PubMed ID: 36984678
[TBL] [Abstract][Full Text] [Related]
2. Anticancer drugs tamoxifen and 4hydroxytamoxifen as effectors of phosphatidylethanolamine lipid polymorphism.
Ortiz J; Teruel JA; Aranda FJ; Ortiz A
Chem Phys Lipids; 2022 Oct; 248():105239. PubMed ID: 36075353
[TBL] [Abstract][Full Text] [Related]
3. Dissimilar action of tamoxifen and 4-hydroxytamoxifen on phosphatidylcholine model membranes.
Ortiz J; Aranda FJ; Teruel JA; Ortiz A
Biophys Chem; 2021 Nov; 278():106681. PubMed ID: 34530285
[TBL] [Abstract][Full Text] [Related]
4. Cryptotanshinone-Induced Permeabilization of Model Phospholipid Membranes: A Biophysical Study.
Ortiz J; Aranda FJ; Teruel JA; Ortiz A
Membranes (Basel); 2024 May; 14(6):. PubMed ID: 38921485
[TBL] [Abstract][Full Text] [Related]
5. Structure and dynamics of phospholipids in membranes elucidated by combined use of NMR and vibrational spectroscopies.
Akutsu H
Biochim Biophys Acta Biomembr; 2020 Sep; 1862(9):183352. PubMed ID: 32407775
[TBL] [Abstract][Full Text] [Related]
6. High efficacy of tamoxifen-loaded L-lysine coated magnetic iron oxide nanoparticles in cell cycle arrest and anti-cancer activity for breast cancer therapy.
Rostami S; Tafvizi F; Kheiri Manjili HR
Bioimpacts; 2022; 12(4):301-313. PubMed ID: 35975200
[No Abstract] [Full Text] [Related]
7. Modulation of tamoxifen-induced hepatotoxicity by tamoxifen-phospholipid complex.
Jena SK; Suresh S; Sangamwar AT
J Pharm Pharmacol; 2015 Sep; 67(9):1198-206. PubMed ID: 25904227
[TBL] [Abstract][Full Text] [Related]
8. Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization.
Shete H; Patravale V
Int J Pharm; 2013 Sep; 454(1):573-83. PubMed ID: 23535345
[TBL] [Abstract][Full Text] [Related]
9. Structure and orientation of the mammalian antibacterial peptide cecropin P1 within phospholipid membranes.
Gazit E; Miller IR; Biggin PC; Sansom MS; Shai Y
J Mol Biol; 1996 May; 258(5):860-70. PubMed ID: 8637016
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation.
Jain AS; Goel PN; Shah SM; Dhawan VV; Nikam Y; Gude RP; Nagarsenker MS
Biomed Pharmacother; 2014 May; 68(4):429-38. PubMed ID: 24721327
[TBL] [Abstract][Full Text] [Related]
11. Interaction of a peptide model of a hydrophobic transmembrane alpha-helical segment of a membrane protein with phosphatidylethanolamine bilayers: differential scanning calorimetric and Fourier transform infrared spectroscopic studies.
Zhang YP; Lewis RN; Hodges RS; McElhaney RN
Biophys J; 1995 Mar; 68(3):847-57. PubMed ID: 7756552
[TBL] [Abstract][Full Text] [Related]
12. Development of tamoxifen-phospholipid complex: novel approach for improving solubility and bioavailability.
Jena SK; Singh C; Dora CP; Suresh S
Int J Pharm; 2014 Oct; 473(1-2):1-9. PubMed ID: 24992316
[TBL] [Abstract][Full Text] [Related]
13. Peptide models of the helical hydrophobic transmembrane segments of membrane proteins: interactions of acetyl-K2-(LA)12-K2-amide with phosphatidylethanolamine bilayer membranes.
Zhang YP; Lewis RN; Hodges RS; McElhaney RN
Biochemistry; 2001 Jan; 40(2):474-82. PubMed ID: 11148042
[TBL] [Abstract][Full Text] [Related]
14. Effect of lipid composition on buforin II structure and membrane entry.
Fleming E; Maharaj NP; Chen JL; Nelson RB; Elmore DE
Proteins; 2008 Nov; 73(2):480-91. PubMed ID: 18452210
[TBL] [Abstract][Full Text] [Related]
15. Identification and targeting of selective vulnerability rendered by tamoxifen resistance.
Singh M; Zhou X; Chen X; Santos GS; Peuget S; Cheng Q; Rihani A; Arnér ESJ; Hartman J; Selivanova G
Breast Cancer Res; 2020 Jul; 22(1):80. PubMed ID: 32727562
[TBL] [Abstract][Full Text] [Related]
16. Differences in the mechanism of the inhibitory actions of catecholestrogens, tamoxifen and high concentrations of estrogens on prolactin release by cultured rat pituitary tumor cells.
Lamberts SW; Verleun T
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1117-23. PubMed ID: 2820746
[TBL] [Abstract][Full Text] [Related]
17. Studies on the Interaction of Alyteserin 1c Peptide and Its Cationic Analogue with Model Membranes Imitating Mammalian and Bacterial Membranes.
Aragón-Muriel A; Ausili A; Sánchez K; Rojas A OE; Londoño Mosquera J; Polo-Cerón D; Oñate-Garzón J
Biomolecules; 2019 Sep; 9(10):. PubMed ID: 31557903
[TBL] [Abstract][Full Text] [Related]
18. Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies.
Shete H; Chatterjee S; De A; Patravale V
Int J Pharm; 2013 Sep; 454(1):584-92. PubMed ID: 23535344
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen-loaded folate-conjugate poly[(p-nitrophenyl acrylate)-co-(N-isopropylacrylamide)] sub-microgel as antitumoral drug delivery system.
Blanco MD; Guerrero S; Benito M; Teijón C; Olmo R; Muñíz E; Katime I; Teijón JM
J Biomed Mater Res A; 2010 Dec; 95(4):1028-40. PubMed ID: 20872870
[TBL] [Abstract][Full Text] [Related]
20. Investigation on the interaction between tamoxifen and human holo-transferrin: determination of the binding mechanism by fluorescence quenching, resonance light scattering and circular dichroism methods.
Sarzehi S; Chamani J
Int J Biol Macromol; 2010 Nov; 47(4):558-69. PubMed ID: 20708639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
